Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome

Robert L. Rinkenberger, Gerald V. Naccarelli, William M. Miles, Michael L. Markel, Anne H. Dougherty, Eric N. Prystowsky, James J. Heger, Douglas P. Zipes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thirty-six patients with a history of atrial fibrillation and Wolff-Parkinson-White syndrome were treated with oral encainide, 175 ± 44 ing/day, after undergoing baseline drug-free electrophysiologic studies. The mean age was 38 ± 15 years, with structural heart disease present in only 3 patients. Nine patients had only paroxysmal atrial fibrillation and 27 patients had both atrial fibrillation and atrioventricular reciprocating tachycardia (AVRT). Symptoms were present for a mean of 195 ± 168 months and were treated with an average of 2.7 ± 1.6 drugs before encainide. Anterograde block in the accessory pathway occurred in 12 of 30 patients (40%) and retrograde block accessory pathway occurred in 10 of 24 patients in whom comparison could be made. AVRT was initiated in 29 of 36 patients during the control study and could be initiated in 19 of 29 patients while receiving encainide. Drug efficacy was determined by the clinical response judged completely effective, partially effective or ineffective. During a mean follow-up of 30.1 ± 25 months, 24 patients (67%) continued to take encainide. Encainide was completely effective in 14 of 24 patients and partially effective in another 7 patients. Noncardiac side effects were mild and generally resolved, and required discontinuance in only 1 patient. More frequent AVRT occurred in 2 patients, but was managed with dose reduction and the addition of a β blocker. Three patients had ventricular tachycardia requiring discontinuance; however 2 of 3 patients had a history of ventricular tachycardia before receiving encainide. Encainide is an effective and safe agent for treating atrial fibrillation in patients with Wolff-Parkinson-White syndrome.

Original languageEnglish
JournalThe American Journal of Cardiology
Volume62
Issue number19
DOIs
StatePublished - Dec 20 1988

Fingerprint

Encainide
Wolff-Parkinson-White Syndrome
Atrial Fibrillation
Reciprocating Tachycardia
Ventricular Tachycardia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rinkenberger, R. L., Naccarelli, G. V., Miles, W. M., Markel, M. L., Dougherty, A. H., Prystowsky, E. N., ... Zipes, D. P. (1988). Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. The American Journal of Cardiology, 62(19). https://doi.org/10.1016/0002-9149(88)90012-4

Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. / Rinkenberger, Robert L.; Naccarelli, Gerald V.; Miles, William M.; Markel, Michael L.; Dougherty, Anne H.; Prystowsky, Eric N.; Heger, James J.; Zipes, Douglas P.

In: The American Journal of Cardiology, Vol. 62, No. 19, 20.12.1988.

Research output: Contribution to journalArticle

Rinkenberger, RL, Naccarelli, GV, Miles, WM, Markel, ML, Dougherty, AH, Prystowsky, EN, Heger, JJ & Zipes, DP 1988, 'Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome', The American Journal of Cardiology, vol. 62, no. 19. https://doi.org/10.1016/0002-9149(88)90012-4
Rinkenberger RL, Naccarelli GV, Miles WM, Markel ML, Dougherty AH, Prystowsky EN et al. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. The American Journal of Cardiology. 1988 Dec 20;62(19). https://doi.org/10.1016/0002-9149(88)90012-4
Rinkenberger, Robert L. ; Naccarelli, Gerald V. ; Miles, William M. ; Markel, Michael L. ; Dougherty, Anne H. ; Prystowsky, Eric N. ; Heger, James J. ; Zipes, Douglas P. / Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. In: The American Journal of Cardiology. 1988 ; Vol. 62, No. 19.
@article{e531dbf8281e4c7ea3da3892feef6584,
title = "Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome",
abstract = "Thirty-six patients with a history of atrial fibrillation and Wolff-Parkinson-White syndrome were treated with oral encainide, 175 ± 44 ing/day, after undergoing baseline drug-free electrophysiologic studies. The mean age was 38 ± 15 years, with structural heart disease present in only 3 patients. Nine patients had only paroxysmal atrial fibrillation and 27 patients had both atrial fibrillation and atrioventricular reciprocating tachycardia (AVRT). Symptoms were present for a mean of 195 ± 168 months and were treated with an average of 2.7 ± 1.6 drugs before encainide. Anterograde block in the accessory pathway occurred in 12 of 30 patients (40{\%}) and retrograde block accessory pathway occurred in 10 of 24 patients in whom comparison could be made. AVRT was initiated in 29 of 36 patients during the control study and could be initiated in 19 of 29 patients while receiving encainide. Drug efficacy was determined by the clinical response judged completely effective, partially effective or ineffective. During a mean follow-up of 30.1 ± 25 months, 24 patients (67{\%}) continued to take encainide. Encainide was completely effective in 14 of 24 patients and partially effective in another 7 patients. Noncardiac side effects were mild and generally resolved, and required discontinuance in only 1 patient. More frequent AVRT occurred in 2 patients, but was managed with dose reduction and the addition of a β blocker. Three patients had ventricular tachycardia requiring discontinuance; however 2 of 3 patients had a history of ventricular tachycardia before receiving encainide. Encainide is an effective and safe agent for treating atrial fibrillation in patients with Wolff-Parkinson-White syndrome.",
author = "Rinkenberger, {Robert L.} and Naccarelli, {Gerald V.} and Miles, {William M.} and Markel, {Michael L.} and Dougherty, {Anne H.} and Prystowsky, {Eric N.} and Heger, {James J.} and Zipes, {Douglas P.}",
year = "1988",
month = "12",
day = "20",
doi = "10.1016/0002-9149(88)90012-4",
language = "English",
volume = "62",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "19",

}

TY - JOUR

T1 - Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome

AU - Rinkenberger, Robert L.

AU - Naccarelli, Gerald V.

AU - Miles, William M.

AU - Markel, Michael L.

AU - Dougherty, Anne H.

AU - Prystowsky, Eric N.

AU - Heger, James J.

AU - Zipes, Douglas P.

PY - 1988/12/20

Y1 - 1988/12/20

N2 - Thirty-six patients with a history of atrial fibrillation and Wolff-Parkinson-White syndrome were treated with oral encainide, 175 ± 44 ing/day, after undergoing baseline drug-free electrophysiologic studies. The mean age was 38 ± 15 years, with structural heart disease present in only 3 patients. Nine patients had only paroxysmal atrial fibrillation and 27 patients had both atrial fibrillation and atrioventricular reciprocating tachycardia (AVRT). Symptoms were present for a mean of 195 ± 168 months and were treated with an average of 2.7 ± 1.6 drugs before encainide. Anterograde block in the accessory pathway occurred in 12 of 30 patients (40%) and retrograde block accessory pathway occurred in 10 of 24 patients in whom comparison could be made. AVRT was initiated in 29 of 36 patients during the control study and could be initiated in 19 of 29 patients while receiving encainide. Drug efficacy was determined by the clinical response judged completely effective, partially effective or ineffective. During a mean follow-up of 30.1 ± 25 months, 24 patients (67%) continued to take encainide. Encainide was completely effective in 14 of 24 patients and partially effective in another 7 patients. Noncardiac side effects were mild and generally resolved, and required discontinuance in only 1 patient. More frequent AVRT occurred in 2 patients, but was managed with dose reduction and the addition of a β blocker. Three patients had ventricular tachycardia requiring discontinuance; however 2 of 3 patients had a history of ventricular tachycardia before receiving encainide. Encainide is an effective and safe agent for treating atrial fibrillation in patients with Wolff-Parkinson-White syndrome.

AB - Thirty-six patients with a history of atrial fibrillation and Wolff-Parkinson-White syndrome were treated with oral encainide, 175 ± 44 ing/day, after undergoing baseline drug-free electrophysiologic studies. The mean age was 38 ± 15 years, with structural heart disease present in only 3 patients. Nine patients had only paroxysmal atrial fibrillation and 27 patients had both atrial fibrillation and atrioventricular reciprocating tachycardia (AVRT). Symptoms were present for a mean of 195 ± 168 months and were treated with an average of 2.7 ± 1.6 drugs before encainide. Anterograde block in the accessory pathway occurred in 12 of 30 patients (40%) and retrograde block accessory pathway occurred in 10 of 24 patients in whom comparison could be made. AVRT was initiated in 29 of 36 patients during the control study and could be initiated in 19 of 29 patients while receiving encainide. Drug efficacy was determined by the clinical response judged completely effective, partially effective or ineffective. During a mean follow-up of 30.1 ± 25 months, 24 patients (67%) continued to take encainide. Encainide was completely effective in 14 of 24 patients and partially effective in another 7 patients. Noncardiac side effects were mild and generally resolved, and required discontinuance in only 1 patient. More frequent AVRT occurred in 2 patients, but was managed with dose reduction and the addition of a β blocker. Three patients had ventricular tachycardia requiring discontinuance; however 2 of 3 patients had a history of ventricular tachycardia before receiving encainide. Encainide is an effective and safe agent for treating atrial fibrillation in patients with Wolff-Parkinson-White syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0024260903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024260903&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(88)90012-4

DO - 10.1016/0002-9149(88)90012-4

M3 - Article

VL - 62

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 19

ER -